Spots Global Cancer Trial Database for Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Official Title: A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT02659059
Conditions
Study Description
Brief Summary: The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sharp Memorial Hospital, San Diego, California, United States
Cancer Center Of Central Connecticut, Plainville, Connecticut, United States
Cleveland Clinic Florida, Weston, Florida, United States
Winship Cancer Institute., Atlanta, Georgia, United States
Summit Cancer Care, Savannah, Georgia, United States
Cancer Center Of Kansas, Wichita, Kansas, United States
University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States
Johns Hopkins Cancer Center, Baltimore, Maryland, United States
Local Institution - 0029, Boston, Massachusetts, United States
Local Institution - 0030, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Local Institution - 0015, Lincoln, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Local Institution - 0036, Albuquerque, New Mexico, United States
Lovelace Cancer Care, Albuquerque, New Mexico, United States
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
New Mexico Cancer Care Center, Albuquerque, New Mexico, United States
The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States
Local Institution - 0010, Mineola, New York, United States
Memorial Sloan Kettering Nassau, New York, New York, United States
Duke University, Durham, North Carolina, United States
Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States
The Ohio State University, Columbus, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Local Institution - 0006, Pittsburgh, Pennsylvania, United States
Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States
Tennessee Oncology, PLLC - SCRI - PPDS, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Local Institution - 0022, Kingston, Ontario, Canada
Local Institution - 0023, Sault Ste Marie, Ontario, Canada
Csss De St-Jerome, St. Jerome, Quebec, Canada
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
